Sign in

    Samuel England

    CFA-qualified Equity Analyst at Berenberg

    Sam England is a CFA-qualified Equity Analyst at Berenberg, specializing in healthcare and medical technology sector research with a focus on companies such as Medacta International. He provides investment analysis and recommendations for Medacta and other leading firms in the medtech industry, drawing on a strong foundation in financial research and sector expertise. England has established a reputation for rigorous analysis and client-facing advisory at Berenberg's London office, leveraging advanced analytical skills gained through his CFA credential and prior experience in the investment industry. His career demonstrates deep sector knowledge, quantitative research capabilities, and a commitment to delivering high-quality investment insights for institutional clients.

    Samuel England's questions to SMITH & NEPHEW (SNN) leadership

    Samuel England's questions to SMITH & NEPHEW (SNN) leadership • Q4 2023

    Question

    Asked for clarification on whether positive pricing was across all segments, the drivers for growth in Wound Devices, and the specific 12-Point Plan initiatives impacting that growth.

    Answer

    Positive pricing was achieved across all three business units and across geographies, not just in aggregate. The growth in negative pressure wound therapy is primarily driven by the new product launch of RENASYS EDGE, which is in its early stages and is expected to be a multiyear growth platform.

    Ask Fintool Equity Research AI